MESOBLAST LIMITED - Announcements

Market Cap $1.113B Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

MSB	MoU for Confirmatory Trial for GI Bleeding in LVAD Patients	PRICE SENSITIVE	27/03/19		Share
MSB	MSB Licensee Files For Skin Disease Marketing Approval	PRICE SENSITIVE	25/03/19		Share
MSB	Joseph R. Swedish Appointed Mesoblast Chairman		22/03/19		Share
MSB	Change in substantial holding		18/03/19		Share
MSB	Upcoming U.S. Investor Conferences		13/03/19		Share
MSB	Mesoblast Provides Half Year Results and Corporate Update	PRICE SENSITIVE	21/02/19		Share
MSB	Half Year Financial Results Presentation		21/02/19		Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	21/02/19		Share
MSB	Final Patient Dosed in Mesoblast P3 Heart Failure Trial		19/02/19		Share
MSB	Mesoblast Newsletter on Advanced and End-Stage Heart Failure		19/02/19		Share
MSB	Change in substantial holding		11/02/19		Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19		Share
MSB	MSB Draws US$15 Million From Existing Facility	PRICE SENSITIVE	14/01/19		Share
MSB	MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase		08/01/19		Share
MSB	Change of Director's Interest Notices		08/01/19		Share
MSB	P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment	PRICE SENSITIVE	07/01/19		Share
MSB	Cleansing notice and Appendix 3B		07/01/19		Share
MSB	Mesoblast Corporate Review		28/12/18		Share
MSB	Mesoblast to Present at 2019 Biotech Showcase in USA		24/12/18		Share
MSB	MSB Makes Executive Appointment To Drive Commercialization		19/12/18		Share
MSB	Meetings Held With FDA Support MSB's Planned GVHD Filing		13/12/18		Share
MSB	Response to ASX query	PRICE SENSITIVE	05/12/18		Share
MSB	Results of Meeting		30/11/18		Share
MSB	Presentation to 2018 Annual General Meeting		30/11/18		Share
MSB	Chairman's Address to Shareholders		30/11/18		Share
MSB	Tasly and MSB Initiate Activities For MPC-150-IM In China		26/11/18		Share
MSB	MSB Provides Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	16/11/18		Share
MSB	First Quarter Results Presentation		16/11/18		Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	16/11/18		Share
MSB	LVAD Results Webcast Presentation	PRICE SENSITIVE	13/11/18		Share
MSB	LVAD Trial Results Provide Potential Regulatory Pathway	PRICE SENSITIVE	12/11/18		Share
MSB	Pause in Trading	PRICE SENSITIVE	12/11/18		Share
MSB	MSB To Host Webcast For Heart Failure Results At AHA		09/11/18		Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18		Share
MSB	Annual Report to shareholders		30/10/18		Share
MSB	Notice of General Meeting/Proxy Form		30/10/18		Share
MSB	Appendix 4G and Corporate Governance Statement		30/10/18		Share
MSB	GVHD and CHF Updates to Emerging Leaders Conference		25/10/18		Share
MSB	MSB Expands Partnership With JCR For Skin Disease	PRICE SENSITIVE	24/10/18		Share
MSB	Change in substantial holding		16/10/18		Share
MSB	Completion of Tasly Transaction, and Appendix 3B	PRICE SENSITIVE	12/10/18		Share
MSB	Release of shares from voluntary escrow		11/10/18		Share
MSB	End-Stage HF Results Selected For AHA Scientific Sessions		02/10/18		Share
MSB	Mesoblast Cardiac Cell Therapy In Children		25/09/18		Share
MSB	Day 180 Survival Outcomes In aGvHD Phase 3 Trial	PRICE SENSITIVE	20/09/18		Share
MSB	Tasly Receives Approvals For Transaction With MSB	PRICE SENSITIVE	17/09/18		Share
MSB	Mesoblast Reports on Annual and Fourth Quarter Results	PRICE SENSITIVE	30/08/18		Share
MSB	Annual Financial Results Presentation		30/08/18		Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	30/08/18		Share
MSB	UPDATE ON TASLY TRANSACTION	PRICE SENSITIVE	29/08/18		Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18		Share
MSB	Initial Director's Interest Notice		18/07/18	62.49KB	Share
MSB	MSB Enters Into Cardiovascular Alliance For China With Tasly	PRICE SENSITIVE	17/07/18	80.49KB	Share
MSB	Director Appointment/Resignation		11/07/18	89.85KB	Share
MSB	Appendix 3B		10/07/18	184.33KB	Share
MSB	MSB Enters Into US$50M Financing With NovaQuest Capital	PRICE SENSITIVE	02/07/18	80.37KB	Share
MSB	Initial and Final Directors' Interest Notices		25/06/18	140.45KB	Share
MSB	ISSCR Presentation on P3 GVHD Trial Survival Benefits		22/06/18	1.77MB	Share
MSB	Key Day 100 Survival Results In P3 GvHD Trial	PRICE SENSITIVE	21/06/18	76.22KB	Share
MSB	Director Appointment/Resignation		19/06/18	74.62KB	Share
MSB	MSB Provides Q3 Financial Results and Operational Highlights		31/05/18	212.11KB	Share
MSB	Mesoblast Appoints New Chief Financial Officer		31/05/18	74.97KB	Share
MSB	Third Quarter Results Presentation		31/05/18	965.73KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	31/05/18	515.82KB	Share
MSB	Partnership For Allogeneic Cell-based Cancer Immunotherapies	PRICE SENSITIVE	29/05/18	77.36KB	Share
MSB	Cleansing notice and Appendix 3B		15/05/18		Share
MSB	MSB P3 Results For GVHD Presented At ISCT Meeting		08/05/18		Share
MSB	MSB Cell Therapies Featured At Vatican Healthcare Conference		01/05/18		Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18		Share
MSB	MSB Clinical Program Update For MPC-150-IM In Heart Failure		18/04/18		Share
MSB	Mesoblast Phase 3 CLBP Trial Completes Enrollment		29/03/18		Share
MSB	Change in substantial holding		09/03/18		Share
MSB	MSB Enters Into $75 Million Non-Dilutive Credit Facility	PRICE SENSITIVE	07/03/18		Share
MSB	Mesoblast Provides Half Year Results and Corporate Update		28/02/18		Share
MSB	Half Year Results Presentation		28/02/18		Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	28/02/18		Share
MSB	GVHD Day 28 Results Presentation	PRICE SENSITIVE	23/02/18		Share
MSB	Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial	PRICE SENSITIVE	22/02/18		Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18		Share
MSB	Appendix 3B with prospectus	PRICE SENSITIVE	19/01/18		Share
MSB	Presentation to J.P. Morgan 2018 Healthcare Conference		12/01/18		Share
MSB	Presentation at JP Morgan Healthcare Conference		11/01/18		Share
MSB	Change of Director's Interest Notice		22/12/17		Share
MSB	Mesoblast Receives RMAT For LVAD Heart Failure Patients	PRICE SENSITIVE	21/12/17		Share
MSB	Release of shares from voluntary escrow		20/12/17		Share
MSB	Mesoblast's P3 GVHD Trial Completes Enrollment	PRICE SENSITIVE	20/12/17		Share
MSB	Mesoblast Grants TiGenix License For Treatment of Fistulae	PRICE SENSITIVE	15/12/17		Share
MSB	MSB Named Global Technology Leader In Cell Therapy Industry	PRICE SENSITIVE	08/12/17		Share
MSB	Change in substantial holding		07/12/17		Share
MSB	Change in substantial holding		05/12/17		Share
MSB	Response to ASX Aware Letter Query	PRICE SENSITIVE	17/11/17		Share
MSB	Results of Meeting		16/11/17		Share
MSB	CEO Presentation to 2017 Annual General Meeting		16/11/17		Share
MSB	Chairman's Address to Shareholders		16/11/17		Share
MSB	Ceasing to be a substantial holder		15/11/17		Share
MSB	Mesoblast Provides Corporate Update and Q1 Financial Results	PRICE SENSITIVE	15/11/17		Share
MSB	First Quarter Results Presentation		15/11/17		Share
MSB	First Quarter Results On Form 6K	PRICE SENSITIVE	15/11/17		Share
MSB	Becoming a substantial holder		13/11/17		Share
MSB	RA Phase 2 Trial Results Presented At ACR Annual Meeting	PRICE SENSITIVE	13/11/17		Share

MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19	PRICE SENSITIVE		Share
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19	PRICE SENSITIVE		Share
MSB Joseph R. Swedish Appointed Mesoblast Chairman
22/03/19			Share
MSB Change in substantial holding
18/03/19			Share
MSB Upcoming U.S. Investor Conferences
13/03/19			Share
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19	PRICE SENSITIVE		Share
MSB Half Year Financial Results Presentation
21/02/19			Share
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19	PRICE SENSITIVE		Share
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial
19/02/19			Share
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure
19/02/19			Share
MSB Change in substantial holding
11/02/19			Share
MSB Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE		Share
MSB MSB Draws US$15 Million From Existing Facility
14/01/19	PRICE SENSITIVE		Share
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
08/01/19			Share
MSB Change of Director's Interest Notices
08/01/19			Share
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19	PRICE SENSITIVE		Share
MSB Cleansing notice and Appendix 3B
07/01/19			Share
MSB Mesoblast Corporate Review
28/12/18			Share
MSB Mesoblast to Present at 2019 Biotech Showcase in USA
24/12/18			Share
MSB MSB Makes Executive Appointment To Drive Commercialization
19/12/18			Share
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing
13/12/18			Share
MSB Response to ASX query
05/12/18	PRICE SENSITIVE		Share
MSB Results of Meeting
30/11/18			Share
MSB Presentation to 2018 Annual General Meeting
30/11/18			Share
MSB Chairman's Address to Shareholders
30/11/18			Share
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China
26/11/18			Share
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18	PRICE SENSITIVE		Share
MSB First Quarter Results Presentation
16/11/18			Share
MSB First Quarter Financial Results on Form 6-K
16/11/18	PRICE SENSITIVE		Share
MSB LVAD Results Webcast Presentation
13/11/18	PRICE SENSITIVE		Share
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18	PRICE SENSITIVE		Share
MSB Pause in Trading
12/11/18	PRICE SENSITIVE		Share
MSB MSB To Host Webcast For Heart Failure Results At AHA
09/11/18			Share
MSB Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE		Share
MSB Annual Report to shareholders
30/10/18			Share
MSB Notice of General Meeting/Proxy Form
30/10/18			Share
MSB Appendix 4G and Corporate Governance Statement
30/10/18			Share
MSB GVHD and CHF Updates to Emerging Leaders Conference
25/10/18			Share
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18	PRICE SENSITIVE		Share
MSB Change in substantial holding
16/10/18			Share
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18	PRICE SENSITIVE		Share
MSB Release of shares from voluntary escrow
11/10/18			Share
MSB End-Stage HF Results Selected For AHA Scientific Sessions
02/10/18			Share
MSB Mesoblast Cardiac Cell Therapy In Children
25/09/18			Share
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18	PRICE SENSITIVE		Share
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18	PRICE SENSITIVE		Share
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18	PRICE SENSITIVE		Share
MSB Annual Financial Results Presentation
30/08/18			Share
MSB Preliminary Final Report including Appendix 4E
30/08/18	PRICE SENSITIVE		Share
MSB UPDATE ON TASLY TRANSACTION
29/08/18	PRICE SENSITIVE		Share
MSB Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE		Share
MSB Initial Director's Interest Notice
18/07/18		62.49KB	Share
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18	PRICE SENSITIVE	80.49KB	Share
MSB Director Appointment/Resignation
11/07/18		89.85KB	Share
MSB Appendix 3B
10/07/18		184.33KB	Share
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18	PRICE SENSITIVE	80.37KB	Share
MSB Initial and Final Directors' Interest Notices
25/06/18		140.45KB	Share
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits
22/06/18		1.77MB	Share
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18	PRICE SENSITIVE	76.22KB	Share
MSB Director Appointment/Resignation
19/06/18		74.62KB	Share
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/18		212.11KB	Share
MSB Mesoblast Appoints New Chief Financial Officer
31/05/18		74.97KB	Share
MSB Third Quarter Results Presentation
31/05/18		965.73KB	Share
MSB Third Quarter Financial Results on Form 6-K
31/05/18	PRICE SENSITIVE	515.82KB	Share
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18	PRICE SENSITIVE	77.36KB	Share
MSB Cleansing notice and Appendix 3B
15/05/18			Share
MSB MSB P3 Results For GVHD Presented At ISCT Meeting
08/05/18			Share
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference
01/05/18			Share
MSB Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE		Share
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure
18/04/18			Share
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment
29/03/18			Share
MSB Change in substantial holding
09/03/18			Share
MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility
07/03/18	PRICE SENSITIVE		Share
MSB Mesoblast Provides Half Year Results and Corporate Update
28/02/18			Share
MSB Half Year Results Presentation
28/02/18			Share
MSB Half Year Report and Accounts (including Appendix 4D)
28/02/18	PRICE SENSITIVE		Share
MSB GVHD Day 28 Results Presentation
23/02/18	PRICE SENSITIVE		Share
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
22/02/18	PRICE SENSITIVE		Share
MSB Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE		Share
MSB Appendix 3B with prospectus
19/01/18	PRICE SENSITIVE		Share
MSB Presentation to J.P. Morgan 2018 Healthcare Conference
12/01/18			Share
MSB Presentation at JP Morgan Healthcare Conference
11/01/18			Share
MSB Change of Director's Interest Notice
22/12/17			Share
MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients
21/12/17	PRICE SENSITIVE		Share
MSB Release of shares from voluntary escrow
20/12/17			Share
MSB Mesoblast's P3 GVHD Trial Completes Enrollment
20/12/17	PRICE SENSITIVE		Share
MSB Mesoblast Grants TiGenix License For Treatment of Fistulae
15/12/17	PRICE SENSITIVE		Share
MSB MSB Named Global Technology Leader In Cell Therapy Industry
08/12/17	PRICE SENSITIVE		Share
MSB Change in substantial holding
07/12/17			Share
MSB Change in substantial holding
05/12/17			Share
MSB Response to ASX Aware Letter Query
17/11/17	PRICE SENSITIVE		Share
MSB Results of Meeting
16/11/17			Share
MSB CEO Presentation to 2017 Annual General Meeting
16/11/17			Share
MSB Chairman's Address to Shareholders
16/11/17			Share
MSB Ceasing to be a substantial holder
15/11/17			Share
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/17	PRICE SENSITIVE		Share
MSB First Quarter Results Presentation
15/11/17			Share
MSB First Quarter Results On Form 6K
15/11/17	PRICE SENSITIVE		Share
MSB Becoming a substantial holder
13/11/17			Share
MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting
13/11/17	PRICE SENSITIVE		Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last $1.57		Change -0.210(11.8%)		Mkt cap ! $1.113B

Open	High	Low	Value	Volume
$1.72	$1.74	$1.52	$15.63M	9.716M

Buyers (Bids)

No.	Vol.	Price($)
1	5127	$1.57

Sellers (Offers)

Price($)	Vol.	No.
$1.57	44837	4

View Market Depth

No.	Vol.	Price($)
1	2	1.375
1	82	1.370
1	3981	1.365
7	49392	1.360
1	4134	1.355

Price($)	Vol.	No.
1.385	247	1
1.400	4328	1
1.405	12000	2
1.410	18724	1
1.420	12000	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)


Last $1.56		Change -0.210 ( 12.9 %)
Open	High	Low	Volume
$1.71	$1.74	$1.52	1536395
Last updated 15.59pm 15/11/2024 ?

MSB (ASX) Chart